212 related articles for article (PubMed ID: 17854248)
41. Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S; Rey MV; Ratti L; Rascol O
Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
[TBL] [Abstract][Full Text] [Related]
42. Pramipexole and ropinirole for Parkinson's disease.
Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
[No Abstract] [Full Text] [Related]
43. Long-term treatment with pramipexole in restless legs syndrome.
Montplaisir J; Fantini ML; Desautels A; Michaud M; Petit D; Filipini D
Eur J Neurol; 2006 Dec; 13(12):1306-11. PubMed ID: 17116213
[TBL] [Abstract][Full Text] [Related]
44. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
45. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
Cheah BC; Kiernan MC
IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
[TBL] [Abstract][Full Text] [Related]
46. Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.
Arbouw ME; Movig KL; Guchelaar HJ; Poels PJ; van Vugt JP; Neef C; Egberts TC
Eur J Clin Pharmacol; 2008 Oct; 64(10):1021-6. PubMed ID: 18626634
[TBL] [Abstract][Full Text] [Related]
47. Pramipexole: in restless legs syndrome.
McCormack PL; Siddiqui MA
CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
[TBL] [Abstract][Full Text] [Related]
48. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
Lemke MR; Brecht HM; Koester J; Reichmann H
J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
[TBL] [Abstract][Full Text] [Related]
49. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
50. Pramipexole induced psychosis in a patient with restless legs syndrome.
Signorelli MS; Battaglia E; Costanzo MC; Cannavò D
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24049088
[TBL] [Abstract][Full Text] [Related]
51. [The role of low-dose pramipexole in the treatment of treatment-resistant bipolar depression: a case report].
Akdeniz F; Aldemir E; Vahip S
Turk Psikiyatri Derg; 2009; 20(1):94-8. PubMed ID: 19306131
[TBL] [Abstract][Full Text] [Related]
52. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
Seeman P
Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
[TBL] [Abstract][Full Text] [Related]
53. The benefits of pramipexole selection in the treatment of Parkinson's disease.
Silindir M; Ozer AY
Neurol Sci; 2014 Oct; 35(10):1505-11. PubMed ID: 25038745
[TBL] [Abstract][Full Text] [Related]
54. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Zhou CQ; Zhang JW; Wang M; Peng GG
J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
[TBL] [Abstract][Full Text] [Related]
55. Classics in Chemical Neuroscience: Pramipexole.
Wilson SM; Wurst MG; Whatley MF; Daniels RN
ACS Chem Neurosci; 2020 Sep; 11(17):2506-2512. PubMed ID: 32786316
[TBL] [Abstract][Full Text] [Related]
56. Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data.
Dell'Osso B; Ketter TA
Int Clin Psychopharmacol; 2013 Nov; 28(6):297-304. PubMed ID: 24081199
[TBL] [Abstract][Full Text] [Related]
57. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
58. Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report.
Munhoz RP; Fabiani G; Becker N; Teive HAG
J Sex Med; 2009 Apr; 6(4):1177-1180. PubMed ID: 18466265
[TBL] [Abstract][Full Text] [Related]
59. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.
Perugi G; Toni C; Ruffolo G; Frare F; Akiskal H
Pharmacopsychiatry; 2001 Jul; 34(4):137-41. PubMed ID: 11518474
[TBL] [Abstract][Full Text] [Related]
60. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
Moore TJ; Glenmullen J; Mattison DR
JAMA Intern Med; 2014 Dec; 174(12):1930-3. PubMed ID: 25329919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
